Sign inCreate account

Report workspace tools

NCT05140811UNKNOWNanonymous

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS

Sponsor

Source record

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

IMM01, Azacitidine

Indication / condition

AI-normalized

Acute Myeloid Leukemia

Intervention

Source record

IMM01, Azacitidine

Source & freshness

Source record

NCT ID

NCT05140811

Original source

ClinicalTrials.gov

Source last updated

May 24, 2023

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05140811

Title

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Status

UNKNOWN

Phase

PHASE1

Condition raw

Acute Myeloid Leukemia, Myelodysplastic Syndromes

Condition normalized

Acute Myeloid Leukemia, Myelodysplastic Syndromes

Modality raw

small molecule

Modality normalized

small molecule

Target raw

IMM01, Azacitidine

Target normalized

IMM01, Azacitidine

Interventions

IMM01, Azacitidine

Public preview

Source record

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS is a PHASE1 clinical asset sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in Acute Myeloid Leukemia, Myelodysplastic Syndromes. SEO and diligence focus: IMM01, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05140811

Status

UNKNOWN

Phase

PHASE1

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Executive brief

Investment-Ready Snapshot

Phase 1/Phase 2 Study of IMM01 Combined With Azacitidine in Patients With AML and MDS is a PHASE1 clinical asset sponsored by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. in Acute Myeloid Leukemia, Myelodysplastic Syndromes. SEO and diligence focus: IMM01, Azacitidine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 24, 2023
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05140811

Indication

Acute Myeloid Leukemia

Modality

small molecule

Target

IMM01, Azacitidine

Intervention

IMM01, Azacitidine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.